The study was aimed to formulate an extended release matrix tablets of celecoxib and to investigate the influence of different types and concentration of polymers on release of drug. Six formulations namely F1 – F6 were manually designed using different proportions of polymers. The matrix tablets formulations (F1 – F5) were composed of using different polymers such as, hydroxypropyl methylcellulose (HPMC-K4M), carboxymethyl cellulose (CMC), ethylcellulose (EC-10 cps) and Carbopol-940, whereas plain tablets formulation (F6) without polymer contained microcrystalline cellulose (MCC), lactose monohydrate, sodium lauryl sulfate (SLS) and polyvinylpyrrolidone (PVP-K30). The MCC, SLS and PVP-K30 were used in a fixed quantity in all formulations except F6 i.e. 20.7%, 6.7%, and 2%, respectively. Multiple point dissolution was performed in phosphate buffer of pH 7.4. Dissolution profiles indicated that formulations F2 and F3 extended the drug release up to the desired time period of 12 h. DD Solver (an add-in software for MS Excel) was used to analyze the dissolution profile data for drug release kinetics such as first order, Zero-order, Higuchi and Korsmeyer–Peppas models. However, formulation (F3) containing HPMC – K4M as a matrix former showed concentration-independent drug release as highest linearity was observed when zero-order model was applied (R² = 0.933). Release mechanism of formulations F3 was super case-II transport. Fourier transform infrared spectroscopy (FTIR) was used to assess the drug polymers compatibility and no drug– excipients interaction was found. The present study accomplished that ethylcellulose and HPMC can be used successfully to develop an extended release matrix tablet formulation.

该研究旨在配制塞来昔布的缓释基质片剂，并研究不同类型和浓度的聚合物对药物释放的影响。使用不同比例的聚合物手动设计了六种配方，即F1-F6。基质片剂配方（F1-F5）由使用不同的聚合物组成，例如羟丙基甲基纤维素（HPMC-K4M），羧甲基纤维素（CMC），乙基纤维素（EC-10 cps）和Carbopol-940，而普通片剂配方（F6 ）不含聚合物的聚合物包含微晶纤维素（MCC），乳糖一水合物，十二烷基硫酸钠（SLS）和聚乙烯吡咯烷酮（PVP-K30）。MCC，SLS和PVP-K30在F6以外的所有配方中均以固定量使用，分别为20.7％，6.7％和2％。在pH 7.4的磷酸盐缓冲液中进行多点溶解。溶出曲线表明，制剂F2和F3将药物释放延长至所需的12小时时间。DD Solver（MS Excel的附加软件）用于分析药物释放动力学的溶出曲线数据，例如一阶，零阶，Higuchi和Korsmeyer-Peppas模型。但是，含有HPMC – K4M作为基质形成剂的制剂（F3）显示出浓度无关的药物释放，因为在应用零级模型时观察到最高的线性（R Higuchi和Korsmeyer-Peppas模型。但是，含有HPMC – K4M作为基质形成剂的制剂（F3）显示出浓度无关的药物释放，因为在应用零级模型时观察到最高的线性（R Higuchi和Korsmeyer-Peppas模型。但是，含有HPMC – K4M作为基质形成剂的制剂（F3）显示出浓度无关的药物释放，因为在应用零级模型时观察到最高的线性（R²  = 0.933）。制剂F3的释放机理是超级病例II转运。傅里叶变换红外光谱（FTIR）用于评估药物聚合物的相容性，未发现药物与赋形剂的相互作用。本研究完成了乙基纤维素和HPMC可成功用于开发缓释基质片剂的配方。